Asset
NERATINIB
PUMA BIOTECHNOLOGY INC COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (33)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00398567 | phase1_2 | completed | 2007-04-04 | 2009-07-31 | Puma Biotechnology, Inc. | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer |
| NCT00445458 | phase1_2 | completed | 2007-09-11 | 2011-05-01 | Puma Biotechnology, Inc. | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer |
| NCT01128842 | phase1 | completed | 2010-04-01 | 2011-03-01 | Puma Biotechnology, Inc. | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor |
| NCT00397046 | phase1 | completed | 2006-11-01 | 2009-03-01 | Puma Biotechnology, Inc. | A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors |
| NCT01808573 | phase3 | completed | 2013-03-29 | 2018-09-28 | Puma Biotechnology, Inc. | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting |
FDA applications (0)
This company has no applications containing this asset.